MDM2 has been established as a biomarker indicating poor prognosis for individuals
undergoing immune checkpoint inhibitor (ICI) treatment for different malignancies by various …

The management of advanced lung cancer has been transformed with the identification of
targetable oncogenic driver alterations. This includes anaplastic lymphoma kinase (ALK) …

Immune checkpoint blockade has modified the treatment landscape for many types of
tumors, including lung cancer. Still our knowledge on the biology of the interaction between …

Anaplastic lymphoma kinase (ALK) gene rearrangements have been identified in lung
cancer at 3–7% frequency, thus representing an important subset of genetic lesions that …

Undifferentiated endometrial carcinoma (UEC) is a rare and poorly recognized entity,
associated with a poor outcome. The clinical, pathologic, and immunohistochemical features …

Targeting of the programmed cell-death 1 ligand 1 (PD-L1) signal pathway is a promising
treatment strategy in several cancers. The purpose of this study was to evaluate the clinical …

Simple Summary Patients with non-small cell lung cancer (NSCLC) have a number of
possible systemic treatment options, including targeted therapy, chemotherapy …

Immunogenic cell death (ICD) is clinically relevant because cytotoxicants that kill malignant
cells via ICD elicit anticancer immune responses that prolong the effects of chemotherapies …

Abstract Programmed death axis 1 (PD-1) inhibitors have ushered in a new error of cancer
immunotherapeutics for advanced smoking-associated non–small cell lung cancer. Their …

Methods To identify the relevant literature and clinical trials the databases PubMed. gov and
ClinicalTrials. gov were queried with keywords “ALK” and “lung cancer”. PubMed search …